Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the "LENAMAINT" Trial

被引：2
|
作者：
Sockel, Katja [1 ]
Greiner, Jochen [2 ]
Trenschel, Rudolf [3 ]
Unzicker, Christian [4 ]
Kobbe, Guido [5 ]
Finke, Jurgen [6 ]
Germing, Ulrich [7 ]
Mohr, Brigitte [1 ]
Beelen, Dietrich [8 ]
Ehninger, Gerhard [9 ]
Bornhaeuser, Martin [1 ]
Platzbecker, Uwe [1 ]
机构：
[1] Univ Hosp Dresden, Med Clin & Policlin 1, Dresden, Germany
[2] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
[3] Univ Hosp, Clin Bone Marrow Transplantat, Essen, Germany
[4] Wuerzburg Univ, Med Ctr, Dept Internal Med 2, Wurzburg, Germany
[5] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[6] Univ Freiburg Klinikum, Dept Med 1, Freiburg, Germany
[7] Univ Hosp Dusseldorf, Dusseldorf, Germany
[8] Univ Hosp Essen, Dept Bone Marrow Transplantat, Essen, Germany
[9] Univ Hosp Carl Gustav Carus, Med Clin & Policlin 1, D-01307 Dresden, Germany
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3060.3060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：1320 / 1320
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities - Results of the "AZALE" Trial
    Platzbecker, Uwe
    Ganster, Christina
    Neesen, Juergen
    Kuendgen, Andrea
    Goetze, Katharina
    Bug, Gesine
    Shirneshan, Katayoon
    Braulke, Friederike
    Roellig, Christoph
    Naumann, Ralph
    Buessemaker, Eckhard
    Giagounidis, Aristoteles
    Hofmann, Wolf-Karsten
    Germing, Ulrich
    Haase, Detlef
    Ehninger, Gerhard
    BLOOD, 2011, 118 (21) : 1623 - 1623
  • [2] Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
    Sockel, Katja
    Bornhaeuser, Martin
    Mischak-Weissinger, Eva
    Trenschel, Rudolf
    Wermke, Martin
    Unzicker, Christian
    Kobbe, Guido
    Finke, Juergen
    Germing, Ulrich
    Mohr, Brigitte
    Greiner, Jochen
    Beelen, Dietrich
    Thiede, Christian
    Ehninger, Gerhard
    Platzbecker, Uwe
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (09): : E34 - E35
  • [3] Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide
    Giagounidis, Aristoteles A.
    Haase, Sabine
    Platzbecker, Uwe
    Germing, Ulrich
    Lohrbacher, Vera
    Ehninger, Gerhard
    Aul, Carlo
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [4] Lenalidomide reexposure After Short Interruption In Del(5q) MDS Patients at Relapse of Transfusion Dependence
    Radkowski, Robert Marek
    Haase, Sabine
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Banisch, Stefanie
    Heinsch, Michael
    Aul, Carlo
    Giagounidis, Aristoteles
    BLOOD, 2010, 116 (21) : 1204 - 1204
  • [5] Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide
    Follo, M. Y.
    Mongiorgi, S.
    Clissa, C.
    Stoyanova, M.
    Paolini, S.
    Quaranta, M.
    Martinelli, G.
    Manzoli, L.
    Cocco, C.
    Finelli, C.
    LEUKEMIA RESEARCH, 2013, 37 : S28 - S28
  • [6] Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
    Follo, Matilde Y.
    Finelli, Carlo
    Clissa, Cristina
    Mongiorgi, Sara
    Baldazzi, Carmen
    Stanzani, Marta
    Baccarani, Michele
    Cocco, Lucia
    BLOOD, 2013, 122 (21)
  • [7] Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Delaunay, Jacques
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Gardembas, Martine
    Visanica, Sorin
    Bauduer, Frederic
    Turlure, Pascal
    Dahoun, Mehdi
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Delmer, Alain
    de Botton, Stephane
    Berthou, Christian
    Besson, Caroline
    Rea, Delphine
    Lefrere, Francois
    Wattel, Eric
    Rousselot, Philippe
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2009, 114 (22) : 1080 - 1081
  • [8] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (05) : 1033 - 1040
  • [9] A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS
    Shammo, Jamile M.
    Christopherson, Kent W., II
    Karmali, Reem
    Larson, Melissa L.
    Balla, Michelle
    Venugopal, Parameswaran
    BLOOD, 2013, 122 (21)
  • [10] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2014, 28 : 1033 - 1040
12345